expected

CLEO Welcomes former Binance NFT Director Ryan Horn as Global Partnerships Lead

  CLEO, a pioneering RWA (real world asset) technology platform leveraging Web3 to fuse real-world impact with digital asset utility and NFTs, proudly announces the addition of Ryan Horn to its team. As the former Binance NFT Director and a recognized leader in the realms of sports, entertainment, and brand crypto strategies, Ryan will serve as a key advisor and lead for global partnerships. Launched in 2023 with its Marketing for Good proposition (rewarding a prospect’s attention for a tokenized good in the world) and having already onboarded clients such

Moxy.io Welcomes Former UBS CFO Thomas Gustinis to Its Executive Team and to the board of the Moxy Foundation

Zug, Switzerland – Moxy.io proudly announces the appointment of Thomas Gustinis, a key figure in treasury management of UBS, as its previous Global Chief Financial Officer. This landmark hire underscores Moxy.io’s ambition to fortify its leadership team with unparalleled financial expertise and vision, propelling the company towards new horizons in the competitive blockchain and gaming industries. Thomas Gustinis brings to Moxy.io a storied career in global finance, having helmed UBS's treasury operations, where he was instrumental in steering the banking giant through complex financial landscapes and maximizing operational efficiency and

Crypto.com’s Dubai Entity Receives Full Operational Approval

Crypto.com Exchange for Institutional Investors Launches as First Operational Milestone April 9, 2024, Dubai - Crypto.com, trusted by more than 80 million customers worldwide and the industry leader in regulatory compliance, security and privacy, announced today that its Dubai entity, CRO DAX Middle East FZE, has received full operational approval from Dubai’s Virtual Assets Regulatory Authority (VARA) and is launching the Crypto.com Exchange for institutional investors as its first operational milestone. This operational approval follows Crypto.com’s fulfillment of the pre-operational conditions stipulated in the Virtual Asset Service Provider Licence granted

Gome Fin Tech Announced Annual Results of 2023

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Moxy.io Announces Strategic Investment from GDA Capital; Michael Gord to Lead Web3 Initiatives

  Seattle, United States. Moxy.io, a blockchain powered tournament platform and infrastructure provider in the competitive gaming and web3 space, has officially announced a strategic investment from GDA Capital, a leading global digital asset and blockchain investment and capital markets advisory firm. This investment marks a significant milestone for Moxy, as Michael Gord, Founder and CEO of GDA Capital, will also be joining their team as the Head of Web3. Michael Gord's appointment is a testament to the depth of GDA Capital's involvement in Moxy's future. Gord, a seasoned web3

Hard Forks, Soft Forks, Defaults and Coercion

One of the important arguments in the blockchain space is that of whether hard forks or soft forks are the preferred protocol upgrade mechanism. The basic difference between the two is that soft forks change the rules of a protocol by strictly reducing the set of transactions that is valid, so nodes following the old rules will still get on the new chain (provided that the majority of miners/validators implements the fork), whereas hard forks allow previously invalid transactions and blocks to become valid, so clients must upgrade their clients

Verofax facilitates Egyptian EU Export with CBAM Compliance and Lifecycle Assessment Solutions

  Egyptian Businessmen's Association (EBA) convenes export symposium on February 9 CAIRO, Feb 15, 2024 - (ACN Newswire) - The Egyptian Businessmen's Association (EBA) convened a symposium on February 9, chaired by Engineer Majd al-Din al-Manzalawi, Secretary-General and Chairman of the Association’s Industry and Scientific Research Committee, to address the challenges and opportunities presented by the Carbon Border Adjustment Mechanism (CBAM), a law governing manufacturing standards for Egyptian exporters. [caption id="attachment_3095647" align="alignnone" width="780"] The Egyptian Businessmen's Association (EBA) convened to discuss the importance of technology in keeping factories compliant with export

GPO Plus, Inc. (GPOX) Achieves Record Revenues with 25% Quarterly Growth

December 18, 2023 - GPO Plus, Inc. (OTCQB: GPOX), a prominent distribution and manufacturing company specializing in consumer products for convenience stores, gas stations, and specialty retailers, has reported impressive Q2 financial results. The company's gross revenue for the quarter ending October 31, 2023, reached a record $1.21 million, marking a substantial 25% increase from the previous quarter ending July 31, 2023, which reported $970,735 in gross revenues. Key Highlights: Quarterly Revenue Surge: GPOX achieved a remarkable 25% surge in top-line revenue, reaching $1.213 million in the second quarter, up

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial